Barclays Downgrades Tesaro (TSRO) to Hold

Barclays analyst Gena Wang downgraded Tesaro (TSRO) to Hold on December 7 and set a price target of $75. The company’s shares closed on Friday at $73.95.

According to TipRanks.com, Wang is a 5-star analyst with an average return of 21.5% and a 51.4% success rate. Wang covers the Healthcare sector, focusing on stocks such as Logicbio Therapeutics Inc, Sarepta Therapeutics, and Kodiak Sciences Inc.

Currently, the analyst consensus on Tesaro is a Hold with an average price target of $67.19, which is a -9.1% downside from current levels. In a report issued on December 3, Leerink Partners also downgraded the stock to Hold with a $75 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $85 and a one-year low of $23.41. Currently, Tesaro has an average volume of 3.17M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. It focuses on oncology-based therapeutics and its products include: Rolapitant and Niraparib.